Discover the Latest in Biomedical Research Innovation

Stop drowning in data and start building a case. Most preclinical failures aren't technical—they're architectural. Discover why "Evidence Architecture" is the missing framework your biotech needs to survive FDA scrutiny, and hear about the rumored AI breakthrough from CLYTE that could change the game forever.

2025 was the year CLYTE evolved from a hardware startup into a biomedical platform. From validating the CytCut device to launching Sophie AI, we achieved ~50k monthly visitors and 5 million impressions with extreme capital efficiency. Discover how we uncovered a massive market gap in lab protocols and secured our place in the future of lab automation.

CLYTE has officially joined the Google for Startups Cloud Program, a major milestone that validates its proprietary Sophie AI technology. This partnership grants CLYTE access to Google’s advanced computational resources, accelerating the release of Sophie 3.0 in January 2026. With enhanced reliability and deep-context analysis, CLYTE is redefining lab automation. The move sets the stage for a Q1 2026 Seed Round, signaling to investors that CLYTE’s tech stack is scalable and s

The frustrating hunt for the perfect lab protocol is officially over. We are thrilled to announce the launch of Soφ 2.0, a revolutionary update to our AI lab assistant. We’ve supercharged Soφ to be more than just a protocol finder; it's now a comprehensive research partner. Featuring a faster, smarter engine and a vastly expanded knowledgebase, Soφ 2.0 introduces game-changing capabilities.